Compare Novartis AG (NVS) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Novartis AG trades at $148.84 (market cap $271.82B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.36B). The key difference: Novartis AG is far larger — about 199.9× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Novartis AG pays a 3.33% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| NVS | USAS | |
|---|---|---|
Market Cap | $271.82B | $1.36B |
Volume | 1,841,354 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $10.03 |
52-Week Low | $121.80 | $3.59 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $313.15B | $1.29B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $142.41, down 0.99% with a bearish technical signal despite strong fundamentals including 74.74% gross margins and 30.55% ROE. Recent Q2 2026 EPS beat expectations at $2.41 versus $2.17, though Q1 missed. The company announced a $7.8B licensing deal with China's Abogen for mRNA therapy, while facing clinical setbacks in ALS drug development and investor scrutiny over M&A strategy.
The stock presents a mixed outlook with solid profitability and growth potential from new deals, but technical weakness and recent trial failures pose near-term risks. Analyst consensus at $146 target suggests modest upside, though bearish sentiment from 68% hold ratings indicates caution amid pipeline uncertainties and competitive pressures in pharma.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
